Trial Profile
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 27 Feb 2024 Inclusion criteria is updated to reduce minimum inclusion age from 18 years to 12 years, thus including children and adolescents' population also.
- 27 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 27 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.